{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:54:18Z","timestamp":1771462458062,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In autoimmune bullous diseases (AIBDs), autoantibodies loosen molecular adhesions in the skin and\/or mucosa and lead to blisters and erosions. Immunosuppressive drugs reduce mortality of the AIBD; therefore, patients will have to live longer with comorbidities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study aims to determine the quality of life of AIBD patients undergoing systemic treatment while investigating the survey\u2019s relationship with various factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this 2-step cross-sectional study, we initially included 53 consecutive pemphigus patients to investigate reliability and validity of the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaire. Then, we conducted the study on 119 AIBD patients, currently under treatment at an AIBD clinic in Iran.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean TABQOL score for our patients was 13.87\u2009\u00b1\u20097.51. The highest TABQOL was for epidermolysis bullosa acquisita (24\u2009\u00b1\u20098.485) followed by pemphigus foliaceus (20.5\u2009\u00b1\u200914.181) and the lowest for pemphigus vulgaris (13.24\u2009\u00b1\u20096.54). There was no significant difference between patients\u2019 TABQOL scores and their gender, history of rituximab injection, and disease severity scores. We only found a positive correlation between TABQOL and prednisolone dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Treatments of AIBD considerably impact the quality of life of patients and an impairment in quality of life is correlated to higher doses of prednisolone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/jw9.0000000000000004","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T17:01:47Z","timestamp":1655744507000},"page":"e004","source":"Crossref","is-referenced-by-count":8,"title":["Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men"],"prefix":"10.1097","volume":"8","author":[{"given":"Atefeh","family":"Behkar","sequence":"first","affiliation":[{"name":"Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Garmaroudi","sequence":"additional","affiliation":[{"name":"Department of Health Promotion & Education, Associate Professor of Maternal & Child Health, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Nasimi","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakiba","family":"Yousefi","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Khosravi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Illinois, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nika","family":"Kianfar","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology at St. George Hospital, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"10","key":"R1-20231102","first-page":"844","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations.","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"R2-20231102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update.","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"issue":"2","key":"R3-20231102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaad.2008.09.014","article-title":"Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.","volume":"60","author":"Paradisi","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"R4-20231102","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-4632.2004.02501.x","article-title":"Pemphigus: analysis of 1209 cases","volume":"44","author":"Chams-Davatchi","year":"2005","journal-title":"Int J Dermatol"},{"issue":"4","key":"R5-20231102","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.det.2011.06.005","article-title":"Minimizing complications in autoimmune blistering diseases.","volume":"29","author":"Clay","year":"2011","journal-title":"Dermatol Clin"},{"issue":"6","key":"R6-20231102","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1468-3083.2001.00336.x","article-title":"Increased psychiatric morbidity in female outpatients with skin lesions on visible parts of the body.","volume":"81","author":"Picardi","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"R7-20231102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.advms.2016.07.002","article-title":"Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.","volume":"62","author":"Kalinska-Bienias","year":"2017","journal-title":"Adv Med Sci"},{"issue":"10","key":"R8-20231102","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"R9-20231102","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bjd.12623","article-title":"The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"R10-20231102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1015013312456","article-title":"Advancing cross-cultural research on quality of life: observations drawn from the WHOQOL development","volume":"11","author":"Skevington","year":"2002","journal-title":"Qual Life Res"},{"issue":"4","key":"R11-20231102","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4103\/ijdvl.IJDVL_538_16","article-title":"Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: reliability and validity.","volume":"84","author":"Chen","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"R12-20231102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/TJD.TJD_16_19","article-title":"Quality of life in Turkish patients with autoimmune blistering diseases: reliability and validity of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires","volume":"13","author":"Bilgic-Temel","year":"2019","journal-title":"Turkish J Dermatol"},{"issue":"4","key":"R13-20231102","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1590\/abd1806-4841.20197198","article-title":"Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases\u2019 patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires.","volume":"94","author":"Saleh","year":"2019","journal-title":"An Bras Dermatol"},{"key":"R14-20231102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-4632.2011.04946.x","article-title":"Spectrum of autoimmune bullous diseases in Iran: a 10-year review.","volume":"51","author":"Daneshpazhooh","year":"2012","journal-title":"Int J Dermatol"},{"key":"R15-20231102","first-page":"1","article-title":"The efficacy of rituximab in patients with mucous membrane pemphigoid","author":"Amir Dastmalchi","year":"2020","journal-title":"J Dermatol Treat"},{"issue":"9","key":"R16-20231102","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV).","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10083","key":"R17-20231102","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"R18-20231102","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/1203475415582317","article-title":"Loss of work productivity and quality of life in patients with autoimmune bullous dermatoses.","volume":"19","author":"Heelan","year":"2015","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"R19-20231102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijwd.2020.03.043","article-title":"Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: validation of the translated Persian version in pemphigus vulgaris.","volume":"6","author":"Teimourpour","year":"2020","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"R20-20231102","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijwd.2018.08.012","article-title":"Illness perception of patients with pemphigus vulgaris.","volume":"5","author":"Nasimi","year":"2019","journal-title":"Int J Womens Dermatol"}],"container-title":["International Journal of Women\u2019s Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JW9.0000000000000004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T18:27:04Z","timestamp":1698949624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JW9.0000000000000004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/jw9.0000000000000004","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}